Objective      To investigate the clinical characteristics and prognosis analysis of different molecular subtypes of breast cancer.       Methods      Clinical data of 247 patients with histopathologically confirmed resectable breast cancer

who were treated in our hospital  from January 2009 to April 2012

were collected and analyzed in this study. The molecular subtypes were categorized as Luminal A subtype

Lumihal B subtype

human epidermal growth factor receptor-2(HER-2) over-expression subtype and triple negative subtype based on the expression of estrogen receptor(ER)

progesterone receptor(PR)

HER-2 and ki-67 protein. The correlation of prognosis of different molecular subtypes was analyzed.       Results      Among the 247 cases of breast cancer

Luminal A

Lumihal B

HER-2 over-expression and triple negative subtypes accounted for 117 cases(47.4%)

56 cases(22.7%)

15 cases(6.1%) and 59 cases(23.9%)

respectively. There were statistically significant differences in the tissue grading

tumor size and targeted therapy among different molecular subtypes(P0.05). Fisher exact calculation of metastatic sites of each subtype suggested that the metastasis rates of Luminal B and triple negative subtypes were 19.6% and 17.0%

respectively

higher than those of the other subtypes. The most common metastasis site was bone metastasis

without statistically significant differences among different subtypes(P0.05). Univariate and multivariate analysis showed that organization classification and pathological types were independent prognostic factors affecting the disease free survival and the overall survival.       Conclusion      Different subtypes of breast cancer have different clinical characteristics. Luminal B and triple negative subtypes have poor prognosis.